# Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

> **NCT00113165** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 244 (actual)

## Conditions studied

- Epilepsy
- Epilepsy, Partial

## Interventions

- **DRUG:** LAMICTAL extended-release

## Key facts

- **NCT ID:** NCT00113165
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2016-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00113165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00113165, "Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00113165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*